Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cNP8
- Development stage
- Phase 1
- Lead developer
- Neomatrix Therapeutics
- Modality
- Peptides
- Administration
- Intravenous, Topical
01
Overview
cNP8 is a novel bioactive peptide designed for both intravenous and topical treatment of burns within 8 to 24 hours post-injury. It promotes mesenchymal cell growth, proliferation, and migration in vitro and acts synergistically with growth factors including platelet-derived growth factor-BB. Unlike similar peptides, cNP8 is effective topically because it resists both exopeptidases and neutrophil elastase, which are known to play a major role in Fibronectin degradation in burn wound fluid.
- Other names
- cNP8cNP-8cNP 8
02
Targets
NeuraminidaseHSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on cNP8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cNP8.